GMED Globus Medical
- 64.720
- +0.360+0.56%
- 62.325
- -2.395-3.70%
Globus Medical News
Globus Medical(GMED.US) Director Sells US$1.3 Million in Common Stock
$Globus Medical(GMED.US)$ Director Davidar David D sold 20,000 shares of common stock on May 8, 2024 at an average price of $65 for a total value of $1.3 million.Source: Announcement What is statement
Globus Medical Insider Sold Shares Worth $1,300,000, According to a Recent SEC Filing
David D Davidar, Director, on May 08, 2024, sold 20,000 shares in Globus Medical (GMED) for $1,300,000. Following the Form 4 filing with the SEC, Davidar has control over a total of 772,242 shares of
Form 144 | Globus Medical(GMED.US) Director Proposes to Sell 3.39 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 10, $Globus Medical(GMED.US)$ Director Lemaitre Dan intends to sell 52,500 shares of its common stock on May 10, with a total market value of approximately $3.39 million.
Form 144 | Globus Medical(GMED.US) Director Proposes to Sell 693.78K in Common Stocks
SEC FILLINGS DISCLOSED/ May 10, $Globus Medical(GMED.US)$ Director Lemaitre Dan intends to sell 10,800 shares of its common stock on May 10, with a total market value of approximately $693.78K. Sou
Key Takeaways From Globus Medical Analyst Ratings
Globus Medical (NYSE:GMED) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.In the table below, you'll find a summary of their recent ra
Globus Medical Is Maintained at Overweight by Barclays
Globus Medical Is Maintained at Overweight by Barclays
Globus Medical Price Target Raised to $85.00/Share From $83.00 by Barclays
Globus Medical Price Target Raised to $85.00/Share From $83.00 by Barclays
Barclays Maintains Overweight on Globus Medical, Raises Price Target to $85
Barclays analyst Matt Miksic maintains Globus Medical (NYSE:GMED) with a Overweight and raises the price target from $83 to $85.
Barclays Reaffirms Their Buy Rating on Globus Medical (GMED)
Globus Medical's Strong Quarter Tempered by NuVasive Merger Complexities: A Hold Rating
Form 144 | Globus Medical(GMED.US) Director Proposes to Sell 227.32K in Common Stocks
SEC FILLINGS DISCLOSED/ May 8, $Globus Medical(GMED.US)$ Director Davidar David D intends to sell 3,500 shares of its common stock on May 8, with a total market value of approximately $227.32K. Sou
Form 144 | Globus Medical(GMED.US) Director Proposes to Sell 1.3 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 8, $Globus Medical(GMED.US)$ Director Davidar David D intends to sell 20,000 shares of its common stock on May 8, with a total market value of approximately $1.3 million.
Globus Medical Shares Race Higher After Better-Than-Expected Q1 Results
Globus Medical, Inc. (NYSE:GMED) shares are trading higher Wednesday after the company posted better-than-expected first-quarter financial results and raised its fiscal year 2024 guidance. The Details
Sector Update: Health Care Stocks Slipping Wednesday Afternoon
Health care stocks were declining Wednesday afternoon, with the NYSE Health Care Index down 0.4% and the Health Care Select Sector SPDR Fund (XLV) decreasing 0.3%. The iShares Biotechnology ETF (IBB)
Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Upstart Holdings, Inc. (NASDAQ:UPST) fell sharply during Wednesday's session after the company reported first-quarter financial results and issued second-quarter revenue guidance below estim
Sector Update: Health Care
Health care stocks were lower Wednesday afternoon, with the NYSE Health Care Index down 0.3% and the Health Care Select Sector SPDR Fund (XLV) decreasing 0.4%. The iShares Biotechnology ETF (IBB) fell
Globus Medical Is Maintained at Buy by BTIG
Globus Medical Is Maintained at Buy by BTIG
Globus Medical Price Target Raised to $63.00/Share From $60.00 by BTIG
Globus Medical Price Target Raised to $63.00/Share From $60.00 by BTIG
BTIG: Maintains Globus Medical (GMED.US) rating, adjusted from buy to buy rating, and adjusted target price from $60.00 to $63.00.
BTIG: Maintains Globus Medical (GMED.US) rating, adjusted from buy to buy rating, and adjusted target price from $60.00 to $63.00.
Globus Medical Shares Rise After Stifel, Truist Adjust Price Targets Upwards
Globus Medical (GMED) shares rose by more than 21% in recent trading Wednesday after Stifel and Truist Securities raised their respective price targets on the company's stock. Stifel raised Globus Med
Analysis
Price Target
No Data
